RIPK3 and lupus nephritis: The RIPK3 inhibitor, GSK ́872 [49,50], which binds and inhibits catalytic activity of the kinase domain of RIPK3 [49,51], has also shown protection in several mouse models, including acute lung injury [52] and lupus nephritis [53].